Ischemic Stroke
Conditions
Brief summary
Acute ischaemic stroke (AIS) results in high rates of neurological morbidity and mortality, especially in patients with large vessel occlusion (LVO). Endovascular therapy (EVT) has been approved as the most effective treatment for patients with LVO , but about half patients undergoing EVT did not achieve good outcome. The mechanisms of poor prognosis are complex. How to accurately identify serological biomarkers related to patients' clinical prognosis is an important research topic nowadays.
Interventions
PROCEDUREendovascular treatment
all patients with anterior circulation large vessel occlusion will receive endovascular treatment.
Sponsors
General Hospital of Shenyang Military Region
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Inclusion criteria
1. Age: 18-80 years; 2. Patients with acute anterior circulation large vessel occlusion within 24 hours of onset who will receive endovascular treatment; 3. Pre-stroke mRS: 0-1; 4. Baseline NIHSS: ≥6; 5. Signed informed consent.
Exclusion criteria
1. The presence of contraindications to internal jugular vein cannulation; 2. Receiving intravenous thrombolysis; 3. Haemorrhagic stroke (cerebral haemorrhage or subarachnoid haemorrhage); 4. Coagulation disorders, systemic bleeding tendency, thrombocytopenia (\<100×109/L); 5. Severe cardiac, hepatic or renal insufficiency (ALT or AST elevated more than 2 times the upper limit of normal value, or serum creatinine elevated more than 1.5 times the upper limit of normal value or in need of dialysis) or other serious medical diseases; 6. Severe uncontrolled hypertension (systolic blood pressure greater than 200 mmHg or diastolic blood pressure greater than 110 mmHg); 7. Pregnant or lactating women; 8. Other conditions who are not suitable for this trial by investigator.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Dynamic changes in serum biomarkers after endovascular treatment | from the baseline to immediately, 30 minutes, 6 hours, and 24 hours after endovascular treatment | These biomarkers will be identified based on proteomic methods |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| favourable functional outcome, defined as modified Rankin Scale (mRS) 0-2 | 90±7 days | mRS ranges from 0-6, high score means poor outcome |
| excellent functional outcome, defined as modified Rankin Scale (mRS) 0-1 | 90±7 days | mRS ranges from 0-6, high score means poor outcome |
| distribution of modified Rankin Scale (mRS) score | 90±7 days | mRS ranges from 0-6, high score means poor outcome |
| early neurological improvement, defined as 4 or more decrease in National Institute of Health stroke scale (NIHSS) | 24±8 hours | NIHSS ranges from 0-22, with high score meaning severe neurological deficit. |
| changes in National Institute of Health stroke scale (NIHSS) | 24±8 hours | NIHSS ranges from 0-22, with high score meaning severe neurological deficit. |
| symptomatic intracranial hemorrhage (sICH) | 24±8 hours | sICH is defined as an increase in 4 or more points on the NIHSS |
| occurence of new stroke or other vascular events | 90±7 days | — |
Countries
China
Outcome results
None listed